Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01830426 · ClinicalTrials.gov registry record
Circulating Tumor Cells in Non-Small Cell Lung Carcinoma
A clinical trial of Primary Lung Cancer, sponsored by Epic Sciences.
- Completed
- Registry status
- 232
- Enrollment target
- 3
- Study locations
NCT01830426 is a study of Primary Lung Cancer that has completed, run by Epic Sciences. The registered enrollment target is 232 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT01830426, a study of Primary Lung Cancer, has completed, sponsored by Epic Sciences.
- COMPLETED
- Registry status
- 232 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to establish the circulating tumor cell (CTC) assay as a surrogate for tissue diagnosis of suspected primary lung cancer. This is done through evaluating clinical and molecular markers to stratify the outcome/survival in patients with thoracic malignancies treated at Yale University/Yale-New Haven Hospital, University of California San Diego/Moores Cancer Center, Billings Clinic Cancer Center.
Conditions Studied
Study Locations (3)
California
- Moores Cancer Center - La Jolla
Connecticut
- Yale University - New Haven
Montana
- Billings Clinic Cancer Center - Billings
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2012-11 |
| Est. Completion | 2016-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01830426
The ClinicalTrials.gov registry entry for NCT01830426 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Epic Sciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT01830426 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Connecticut, Montana.
Frequently Asked Questions
What is clinical trial NCT01830426 about?
NCT01830426 is a clinical study titled "Circulating Tumor Cells in Non-Small Cell Lung Carcinoma". The purpose of this study is to establish the circulating tumor cell (CTC) assay as a surrogate for tissue diagnosis of suspected primary lung cancer. This is done through evaluating clinical and molecular markers to stratify the outcome/survival in patients with thoracic malignancies treated at Yal...
What is the current status of trial NCT01830426?
This trial is currently completed. The enrollment target is 232 participants. The study started on 2012-11. Estimated completion is 2016-01.
What conditions does trial NCT01830426 study?
This clinical trial studies the following conditions: Primary Lung Cancer.
Who is sponsoring clinical trial NCT01830426?
This trial is sponsored by Epic Sciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01830426 being conducted?
This trial has 3 study locations across California, Connecticut, Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.